Latest From Wilex AG
A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.
Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.
BioNotebook: PaxVax, Bluebird/Pregenen, RedHill/Wilex, CureVac/Sanofi Pasteur, Synchroneuron, Advanced Cell, Raptor, Ablynx
PaxVax has 1st Phase III success; Bluebird buys Pregenen; RedHill acquires Wilex asset; Sanofi options CureVac vaccine; Synchroneuron gets VC funding; and Advanced Cell, Raptor, Ablynx raise new cash.
Merck Serono has expanded its oncology activities into antibody drug conjugates (ADCs) through a deal signed with Cambridge, Massachusetts-based Mersana Therapeutics.
- Large Molecule
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Wilex Biotechnology GMBH
- Western Europe
- Parent & Subsidiaries
- Wilex AG
- Senior Management
Jan Schmidt-Brand, PhD, CFO
Andreas Pahl, Head, R&D
- Contact Info
Phone: (49) 89 41 31 38 0
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.